



TBVI Symposium 2024

January 30-31, 2024

Tuesday January 30, 2024 (*Maison des congrès*)

14.00-14.05 Welcome and Opening: Gerald Voss, Executive Director ad interim, TBVI

1. Fundamental and applied research and novel technologies to innovate the TB vaccine pipeline

Novel insights in mucosal vaccine administration and spatial-temporal patterns of the local immune response in and beyond TB (chair: Olivier Neyrolles)

14:05-14.10 Introduction (Olivier Neyrolles)

14.10-14.30 Brittany Hartwell - University Minnesota, Minneapolis: [“Harnessing albumin hitchhiking for enhanced uptake of mucosal vaccines against infectious disease”](#)

14.30-14.50 David Schreiner - University Basel: [“Space, the final frontier?”](#)

14.50-15.10 Emma Lefrancais - CNRS-IPBS, Toulouse: [“Intravital imaging of lung immune responses”](#)

15:10-15.30 Klaas van Gisbergen - Champalimaud Foundation, Lisbon: [“Immunological Memory of the Tissues”](#)

15.30-15.40 TBVI Talent Awards (Frank Verreck)

15:40-15.55 Paul Ogongo - University of California San Francisco: [“Distinct *Mtb* antigens under diversifying evolutionary selection induce Th17 responses in controlled human tuberculosis”](#)

15.55-16.10 Discussion and Summary (All, Olivier Neyrolles)

16.10-16.40 Coffee break and Group photo

Novel TB vaccine candidates: Innovative approaches, in vivo- / in vitro-models, tools and technologies (chair: Andrea Cooper)

16.40-16.45 Introduction (Andrea Cooper)

16.45-17.05 David Lewinsohn - OHS University, Portland: [“DURTS as a Target for Vaccination”](#)

17.05-17.25 Björn Corleis - FLI, Isle of Riems: [“Inter-species comparison of immune responses to novel mucosal vaccine concepts”](#)

17.25-17.45 Tom Scriba - SATVI, Cape Town: [“Inflammatory and T cell biomarkers of disease progression or control of *Mtb*”](#)

17.45-18.05 Thomas Lindenstrøm - Statens Serum Institute, Copenhagen: [“Vaccine-promoted HEVs and T cell trafficking in the *Mtb* infected lung”](#)

18.05-18.20 Juliane Hübner - TissUse, Berlin: “TB Organoid Model – towards an MPS-based assay to test TB vaccines and treatment modalities”

18.20-18.35 Helen McShane - Oxford University: [“Controlled Human Infection Model \(CHIM\)”](#)

18.35-18.45 Discussion and Summary (All, Andrea Cooper)

18.45-18.50 Wrap-up & summary, outlook to Wednesday (Andrea Cooper, Olivier Neyrolles and Elly van Riet)

19.00-20.00 Reception

20.00 Joint dinner



TBVI Symposium 2024

January 30-31, 2024

Wednesday January 31, 2024 (*Maison des congrès*)

08.15-08.20 Welcome and programme of the day (Elly van Riet - TBVI)

2. Accelerating Clinical Development

08.20-08.30 Introduction (Helen McShane)

08.30-08.45 Mark Hatherill - University of Cape Town: [“Overview TB Vaccine Clinical Pipeline”](#)

08.45-09.00 Carlos Martin - University Zaragoza: [“Live attenuated TB vaccine candidate MTBVAC”](#)

09.00-09.15 Sina Brückner - SLS Europe, Hannover: [“Updates on the VPM1002 development”](#)

09.15-09.30 Andy Tran - St George's University of London: [“Development of a Novel Self-Adjuvanting Vaccine Platform for TB”](#)

09.30-09.45 Ann Ginsberg - BMGF, Seattle: [“M72/AS01E update”](#)

09.45-10.00 Alvaro Borges - Statens Serum Institute, Copenhagen: “The TB vaccine H56:IC31: phase 2 prevention of recurrence trial”

10.00-10.30 **Coffee break**

10.30-11.00 Pragmatic design of efficacy trials –

Interactive debate with Mark Hatherill and Frank Cobelens, moderated by Helen McShane

3. Enablers to ensure public health impact

11.00-11.15 Debbie King - Wellcome Trust, London: [TBVI Wellcome](#)

11.15-11.30 Jean Marie Habarugira - Global Health EDCTP3, Brussels: [“Current Research and Innovation Strategy”](#)

11.30-11.45 Ann Ginsberg - BMGF, Seattle: [“TB Vaccine program at BMGF – current and planned activities”](#)

11.45-12.00 Mphatso Phiri - Liverpool School of Tropical Medicine: [“Mtb infection prevalence: implications for estimating population impact of pre- & post-exposure TB vaccines”](#)

12.00-12.15 Birgitte Giersing - WHO, Geneva: [“WHO activities to accelerate TB vaccine development and use”](#)

12.15-12.20 Helen McShane - Oxford University: “The Validate Network”

12.20-12.30 Summary and closure (Elly van Riet)